En-Sheng Ji
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
En-Sheng Ji has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
- Yashuo Zhao
Hebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China
15 shared publications Peng Guan
Department of Physiology, School of Pharmacy, Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050091, P.R. China
10 shared publicationsYa-Shuo Zhao
Department of Physiology, Hebei University of Chinese Medicine, Shijiazhuang, China
9 shared publications- Shengchang Yang
Department of Physiology, Hebei University of Chinese Medicine, Shijiazhuang 050000, China; Hebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Shijiazhuang 050000, China
8 shared publications - Ji-Ren An
Department of Physiology, Institute of Basic Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China
6 shared publications Ji-Xian Song
Hebei Technology Innovation Center of TCM Combined Hydrogen Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China; Department of Physiology, Institute of Integrative Medicine, Hebei University of Chinese Medicine, Shijiazhuang 050200, China
6 shared publications
Latest Publications
- Open Access
- 20 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Hydrogen suppressed tumor growth during chronic intermittent hypoxia via modulating macrophage polarization
Lung cancer remains a major challenge in clinical treatment, as current therapeutic strategies often fail to effectively halt disease progression. Chronic intermittent hypoxia (CIH), a hallmark pathological feature of obstructive sleep apnea (OSA), has been implicated in promoting tumor invasion and metastasis. This study aimed to investigate the potential of hydrogen as an innovative adjunctive therapy for lung cancer. To evaluate the therapeutic effects of hydrogen, both in vitro and in vivo models were established. In vitro, an intermittent hypoxia (IH) tumor cell-macrophage co-culture system was used to assess cell proliferation, migration, and macrophage polarization. In vivo, tumor growth was monitored in a CIH mouse model, and tissue samples were subsequently analyzed via immunohistochemistry and western blot. Our results demonstrated that hydrogen exerted significant antitumor effects in vivo. Mechanistically, this effect was associated with a shift in macrophage polarization toward the pro-inflammatory M1 phenotype and suppression of the CCL2-CCR2 signaling axis. In addition, in vitro studies revealed that hydrogen directly inhibited lung cancer cell survival and migration, and downregulated key components of the CCL2-CCR2 pathway, mirroring the effects observed with a CCR2 inhibitor. These findings highlighted that hydrogen treatment suppressed tumor growth by modulating the tumor immune microenvironment and inhibiting angiogenesis. Collectively, our results suggested that hydrogen may represented a novel and promising therapeutic strategy for lung cancer.
- 20 June 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessHydrogen suppressed tumor growth during chronic intermittent hypoxia via modulating macrophage polarization
Lung cancer remains a major challenge in clinical treatment, as current therapeutic strategies often fail to effectively halt disease progression. Chronic intermittent hypoxia (CIH), a hallmark pathological feature of obstructive sleep apnea (OSA), has been implicated in promoting tumor invasion and metastasis. This study aimed to investigate the potential of hydrogen as an innovative adjunctive therapy for lung cancer. To evaluate the therapeutic effects of hydrogen, both in vitro and in vivo models were established. In vitro, an intermittent hypoxia (IH) tumor cell-macrophage co-culture system was used to assess cell proliferation, migration, and macrophage polarization. In vivo, tumor growth was monitored in a CIH mouse model, and tissue samples were subsequently analyzed via immunohistochemistry and western blot. Our results demonstrated that hydrogen exerted significant antitumor effects in vivo. Mechanistically, this effect was associated with a shift in macrophage polarization toward the pro-inflammatory M1 phenotype and suppression of the CCL2-CCR2 signaling axis. In addition, in vitro studies revealed that hydrogen directly inhibited lung cancer cell survival and migration, and downregulated key components of the CCL2-CCR2 pathway, mirroring the effects observed with a CCR2 inhibitor. These findings highlighted that hydrogen treatment suppressed tumor growth by modulating the tumor immune microenvironment and inhibiting angiogenesis. Collectively, our results suggested that hydrogen may represented a novel and promising therapeutic strategy for lung cancer.
- 9 December 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 169, 115974
Hydrogen alleviates cardiac ferroptosis damage under chronic intermittent hypoxia conditions by targeting Nrf2
- 9 December 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 169, 115974
Hydrogen alleviates cardiac ferroptosis damage under chronic intermittent hypoxia conditions by targeting Nrf2
- 26 October 2025
- Published by Elsevier in Fitoterapia
- Vol. 187, 106941
Shengmaisan combined with Liuwei Dihuang Decoction alleviated CIH-induced glutamate excitotoxicity by IGF1/IGFR signaling pathway
- 26 October 2025
- Published by Elsevier in Fitoterapia
- Vol. 187, 106941
Shengmaisan combined with Liuwei Dihuang Decoction alleviated CIH-induced glutamate excitotoxicity by IGF1/IGFR signaling pathway
- 21 August 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1005, 178078
Hydrogen promoted mitochondrial autophagy and alleviated CIH-induced vascular endothelial cell senescence by regulating oxidative stress
- 21 August 2025
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1005, 178078
Hydrogen promoted mitochondrial autophagy and alleviated CIH-induced vascular endothelial cell senescence by regulating oxidative stress
- 15 July 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 163, 115179
Therapeutic potential of Banxia-Houpu Decoction in alleviating inflammation and myocardial injury in chronic intermittent hypoxia models
- 15 July 2025
- Published by Elsevier in International Immunopharmacology
- Vol. 163, 115179
Therapeutic potential of Banxia-Houpu Decoction in alleviating inflammation and myocardial injury in chronic intermittent hypoxia models
- Open Access
- 26 November 2024
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 16 (1) , 31-45
Role of IGF1/IGFR signaling pathway in neuroprotective effect of Shengmai Dihuang Decoction on CIH-induced cognitive impairment
- 26 November 2024
- Published by Elsevier in Journal of Traditional and Complementary Medicine
- Vol. 16 (1) , 31-45
Open AccessRole of IGF1/IGFR signaling pathway in neuroprotective effect of Shengmai Dihuang Decoction on CIH-induced cognitive impairment
- Open Access
- 25 July 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (14) , e18543
Cardiomyocyte‐specific overexpression of FPN1 diminishes cardiac hypertrophy induced by chronic intermittent hypoxia
The significance of iron in myocardial mitochondria function cannot be underestimated, because deviations in iron levels within cardiomyocytes may have profound detrimental effects on cardiac function. In this study, we investigated the effects of ferroportin 1 (FPN1) on cardiac iron levels and pathological alterations in mice subjected to chronic intermittent hypoxia (CIH). The cTNT‐FPN1 plasmid was administered via tail vein injection to induce the mouse with FPN1 overexpression in the cardiomyocytes. CIH was established by exposing the mice to cycles of 21%–5% FiO 2 for 3 min, 8 h per day. Subsequently, the introduction of hepcidin resulted in a reduction in FPN1 expression, and H9C2 cells were used to establish an IH model to further elucidate the role of FPN1. First, FPN1 overexpression ameliorated CIH‐induced cardiac dysfunction, myocardial hypertrophy, mitochondrial damage and apoptosis. Second, FPN1 overexpression attenuated ROS levels during CIH. In addition, FPN1 overexpression mitigated CIH‐induced cardiac iron accumulation. Moreover, the administration of hepcidin resulted in a reduction in FPN1 levels, further accelerating the CIH‐induced levels of ROS, LIP and apoptosis in H9C2 cells. These findings indicate that the overexpression of FPN1 in cardiomyocytes inhibits CIH‐induced cardiac iron accumulation, subsequently reducing ROS levels and mitigating mitochondrial damage. Conversely, the administration of hepcidin suppressed FPN1 expression and worsened cardiomyocyte iron toxicity injury.
- 25 July 2024
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 28 (14) , e18543
Open AccessCardiomyocyte‐specific overexpression of FPN1 diminishes cardiac hypertrophy induced by chronic intermittent hypoxia
The significance of iron in myocardial mitochondria function cannot be underestimated, because deviations in iron levels within cardiomyocytes may have profound detrimental effects on cardiac function. In this study, we investigated the effects of ferroportin 1 (FPN1) on cardiac iron levels and pathological alterations in mice subjected to chronic intermittent hypoxia (CIH). The cTNT‐FPN1 plasmid was administered via tail vein injection to induce the mouse with FPN1 overexpression in the cardiomyocytes. CIH was established by exposing the mice to cycles of 21%–5% FiO 2 for 3 min, 8 h per day. Subsequently, the introduction of hepcidin resulted in a reduction in FPN1 expression, and H9C2 cells were used to establish an IH model to further elucidate the role of FPN1. First, FPN1 overexpression ameliorated CIH‐induced cardiac dysfunction, myocardial hypertrophy, mitochondrial damage and apoptosis. Second, FPN1 overexpression attenuated ROS levels during CIH. In addition, FPN1 overexpression mitigated CIH‐induced cardiac iron accumulation. Moreover, the administration of hepcidin resulted in a reduction in FPN1 levels, further accelerating the CIH‐induced levels of ROS, LIP and apoptosis in H9C2 cells. These findings indicate that the overexpression of FPN1 in cardiomyocytes inhibits CIH‐induced cardiac iron accumulation, subsequently reducing ROS levels and mitigating mitochondrial damage. Conversely, the administration of hepcidin suppressed FPN1 expression and worsened cardiomyocyte iron toxicity injury.
- 28 June 2024
- Published by Elsevier in Phytomedicine
- Vol. 132, 155835
Rosmarinic acid liposomes suppress ferroptosis in ischemic brain via inhibition of TfR1 in BMECs
- 28 June 2024
- Published by Elsevier in Phytomedicine
- Vol. 132, 155835
Rosmarinic acid liposomes suppress ferroptosis in ischemic brain via inhibition of TfR1 in BMECs
- Open Access
- 30 April 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116653
Mechanistic study of Huangqi Guizhi Wuwu decoction amelioration of doxorubicin-induced cardiotoxicity by reducing oxidative stress and inhibiting cellular pyroptosis
- 30 April 2024
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 175, 116653
Open AccessMechanistic study of Huangqi Guizhi Wuwu decoction amelioration of doxorubicin-induced cardiotoxicity by reducing oxidative stress and inhibiting cellular pyroptosis